{"id":"ivabradine-and-metoprolol","safety":{"commonSideEffects":[{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Visual disturbances (ivabradine-related)"}]},"_chembl":{"chemblId":"CHEMBL471737","moleculeType":"Small molecule","molecularWeight":"468.59"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ivabradine is a selective inhibitor of the funny current (If) in cardiac pacemaker cells, slowing heart rate without affecting contractility or blood pressure. Metoprolol is a beta-1 selective antagonist that reduces heart rate and cardiac workload through adrenergic blockade. Together, they provide complementary heart rate reduction for patients with heart failure or angina who require more aggressive rate control.","oneSentence":"This combination reduces heart rate through dual action: ivabradine selectively inhibits the If channel in the sinoatrial node, while metoprolol blocks beta-1 adrenergic receptors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:50:36.323Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Heart failure with reduced ejection fraction (HFrEF) with elevated resting heart rate"},{"name":"Stable angina pectoris"},{"name":"Chronic heart failure"}]},"trialDetails":[{"nctId":"NCT07268170","phase":"PHASE2, PHASE3","title":"Heart Rate Control Before Cardiac Computed Tomography in Adults for the Evaluation of Coronary Artery Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Gødstrup Hospital","startDate":"2025-12-15","conditions":"Coronary Arterial Disease (CAD), Ischemic Heart Disease (IHD)","enrollment":350},{"nctId":"NCT06371222","phase":"PHASE4","title":"Role of Ivabradine on Heart Rate and Quality of Life in Patients With Mitral Stenosis in Sinus Rhythm","status":"COMPLETED","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-02-01","conditions":"Mitral Stenosis","enrollment":42},{"nctId":"NCT05580510","phase":"PHASE2, PHASE3","title":"\" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD \"","status":"UNKNOWN","sponsor":"Instituto Nacional de Cardiologia Ignacio Chavez","startDate":"2023-02-06","conditions":"Congenital Heart Disease, Heart Failure, Heart Failure With Reduced Ejection Fraction","enrollment":160},{"nctId":"NCT05261464","phase":"PHASE4","title":"Heart Rate Controller in Computed Tomography Coronary Angiography","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2021-01-30","conditions":"Heart Rate, Coronary Computed Tomography Angiography","enrollment":246},{"nctId":"NCT00825123","phase":"PHASE4","title":"Effects of Heart Rate Reduction on Central Arterial Pressure in Healthy Individuals","status":"TERMINATED","sponsor":"Bayside Health","startDate":"2008-10","conditions":"Central Arterial Pressure","enrollment":2},{"nctId":"NCT03830957","phase":"NA","title":"Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker","status":"UNKNOWN","sponsor":"Rajaie Cardiovascular Medical and Research Center","startDate":"2018-11-26","conditions":"Heart Failure, CT Angiography, Ischemic Cardiomyopathy","enrollment":200},{"nctId":"NCT01755663","phase":"PHASE4","title":"Comparison of Efficacy of Ivabradine Versus Metoprolol","status":"UNKNOWN","sponsor":"Col. Suthee Panichkul","startDate":"2014-12","conditions":"Coronary Artery Disease","enrollment":60},{"nctId":"NCT01029223","phase":"PHASE4","title":"The Influence of Heart Rate Reduction Upon Central Arterial Pressure in Younger and Older Healthy Individuals","status":"WITHDRAWN","sponsor":"Bayside Health","startDate":"2008-10","conditions":"Blood Pressure","enrollment":42},{"nctId":"NCT00865917","phase":"PHASE2","title":"Cardiovascular Effects of Selective I(f)-Channel Blockade","status":"UNKNOWN","sponsor":"Hannover Medical School","startDate":"2008-11","conditions":"Postural Orthostatic Tachycardia Syndrome","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ivabradine and Metoprolol","genericName":"Ivabradine and Metoprolol","companyName":"Col. Suthee Panichkul","companyId":"col-suthee-panichkul","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces heart rate through dual action: ivabradine selectively inhibits the If channel in the sinoatrial node, while metoprolol blocks beta-1 adrenergic receptors. Used for Heart failure with reduced ejection fraction (HFrEF) with elevated resting heart rate, Stable angina pectoris, Chronic heart failure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}